Program
votoplam
Also written as “Votoplam (blinded)”, “PTC518” and “Votoplam”.
In Novartis's pipeline, Huntingtin modulator
. Its studies are mostly in Huntington Disease, led by Novartis.
Furthest: phase 3, since Jan 7, 20263 company-led studies, 2 open or runningNext primary completion: Jul 16, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 32 open or running | phase 3since Jan 7, 2026 | Apr 27, 2022 | Jul 16, 2029phase 2 · NCT06254482 |
- Named in Novartis’s own pipeline as
HTT227 (votoplam)
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2022First study: phase 2 study in Huntington DiseaseFirst studyNCT05358717 · 159 enrolled · United States, Australia, Austria and more
- Feb 2, 2024Phase 2 study in Huntington DiseaseNCT06254482 · 144 enrolled · Australia, Austria, Canada and more
- Jan 7, 2026Phase 3 study in Huntington DiseasePhase 3 reachedNCT07326709 · 770 planned · United States, Argentina, Australia and more
Ahead
- Jul 16, 2029Primary completion: phase 2 study in Huntington DiseaseNCT06254482
- Apr 2, 2030Primary completion: phase 3 study in Huntington DiseaseNCT07326709
TargetBeta
“Huntingtin modulator”the company's pipeline, read by Claude · source
Other programs on HTT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| L-(+)-methylenetetrahydrofolic acidrule | isofol-medical-ab | phase 3 | 5 |
| SKY-0515rule | skyhawk-therapeutics-inc | phase 3 | 2 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07326709Huntington Disease · United States, Argentina, Australia and more | 3 | Recruiting | Apr 2, 2030 | 770 |
| NCT06254482Huntington Disease · Australia, Austria, Canada and more | 2 | Active, not recruiting | Jul 16, 2029 | 144 |
| NCT05358717Huntington Disease · United States, Australia, Austria and more | 2 | Completed | Feb 7, 2025 | 159 |
How it is read
Names in the registry
- “Votoplam (blinded)”, 1 entry
- “PTC518”, 1 entry
- “Votoplam”, 1 entry
Conditions, from the studies’ own filings
- Huntington Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.